(00625): Stabilization period ended; previously entered the market to purchase a total of 41.9985 million Class B shares
Shein-W (00625) announced that the stabilization period for the global offering ended on Saturday, September 26, 2026 (being the 30th day after the deadline for submitting applications for the Hong Kong public offering). The sponsor and overall coordinator (on its own behalf and on behalf of the international underwriters) did not exercise the over-allotment option during the stabilization period, and the over-allotment option lapsed on Saturday, September 26, 2026. Accordingly, no Class B shares have been or will be issued under the over-allotment option.
(00625) announced that the stabilization period for the global offering ended on Saturday, September 26, 2026 (being the 30th day after the deadline for submitting applications for the Hong Kong public offering). The sponsor and overall coordinator (on its own behalf and on behalf of the international underwriters) did not exercise the over-allotment option during the stabilization period, and the over-allotment option lapsed on Saturday, September 26, 2026. Accordingly, no Class B shares have been or will be issued pursuant to the over-allotment option.
The stabilization actions taken during the stabilization period by Goldman Sachs (Asia) L.L.C., the stabilizing manager, or any of its affiliates, or any person acting on its behalf, are set out as follows:
An aggregate of 41,998,500 Class B shares were over-allocated in the international offering; Goldman Sachs International (an affiliate of the stabilizing manager, Goldman Sachs (Asia) L.L.C.) borrowed an aggregate of 41,998,500 Class B shares from Apex Sight Holdings Limited pursuant to the stock borrowing agreement to cover the over-allocation in the international offering; during the stabilization period, an aggregate of 41,998,500 Class B shares were successively purchased in the market at a price range of HK$35.90 to HK$48.56 per Class B share, in order to facilitate the return of the 41,998,500 Class B shares borrowed from the lender pursuant to the stock borrowing agreement.
Related Articles

Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved

Sichuan Biokin Pharmaceutical (688506.SH): Yizekang included in the breakthrough therapy designation list

FANGZHOU JIANKE (06086) Caina Technology Incentive Plan
Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved

Sichuan Biokin Pharmaceutical (688506.SH): Yizekang included in the breakthrough therapy designation list

FANGZHOU JIANKE (06086) Caina Technology Incentive Plan






